Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Virios Therapeutics Inc VIRI

Healthcare Biotechnology
Virios Therapeutics, Inc. is a development-stage biotechnology company. The Company is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (FM) and Long-COVID (LC). Its lead candidate, IMC-1, is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel... see more

Recent & Breaking News (NDAQ:VIRI)

Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID

GlobeNewswire March 26, 2024

Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire February 29, 2024

Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones

GlobeNewswire February 28, 2024

Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID

GlobeNewswire January 22, 2024

Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

GlobeNewswire January 2, 2024

Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire November 13, 2023

Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

GlobeNewswire November 6, 2023

Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023

GlobeNewswire October 12, 2023

Virios Therapeutics Announces Termination of At-The-Market Sales Agreement

GlobeNewswire September 18, 2023

Virios Therapeutics CEO Greg Duncan to Present at the SHARE(TM)️ Series Investor Event on Monday, September 18, 2023

GlobeNewswire September 12, 2023

Virios Therapeutics Announces Halt to At-The-Market Offering Sales

GlobeNewswire August 14, 2023

Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire August 10, 2023

Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia

GlobeNewswire August 9, 2023

Virios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

GlobeNewswire August 3, 2023

Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study

GlobeNewswire July 17, 2023

Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

GlobeNewswire May 25, 2023

Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia

GlobeNewswire May 15, 2023

Virios Therapeutics Announces First Quarter 2023 Financial Results

GlobeNewswire May 11, 2023

Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

GlobeNewswire May 4, 2023

Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of Fibromyalgia

GlobeNewswire April 24, 2023